E
Edith A. Zang
Researcher at Columbia University
Publications - 26
Citations - 4570
Edith A. Zang is an academic researcher from Columbia University. The author has contributed to research in topics: Hepatitis B & Hepatitis B virus. The author has an hindex of 21, co-authored 26 publications receiving 4430 citations. Previous affiliations of Edith A. Zang include Manhattan Eye, Ear and Throat Hospital & New York Blood Center.
Papers
More filters
Journal ArticleDOI
Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.
Wolf Szmuness,Cladd E. Stevens,Edward J. Harley,Edith A. Zang,William R. Oleszko,Daniel C. William,Richard Sadovsky,John Morrison,Aaron Kellner +8 more
TL;DR: In this article, the efficacy of an inactivated hepatitis B vaccine in a randomized, double-blind trial in 1083 homosexual men known to be at high risk for hepatitis B virus infection was evaluated.
Journal ArticleDOI
Differences in Lung Cancer Risk Between Men and Women: Examination of the Evidence
Edith A. Zang,Ernst L. Wynder +1 more
TL;DR: Women were more likely to be never-smokers than men, particularly those with the squamous/epidermoid-type cancer, and the earlier finding that the ORs for major lung cancer types are consistently higher for women than for men at every level of exposure to cigarette smoke was confirmed.
Journal ArticleDOI
Fluorescein angiography complication survey.
Lawrence A. Yannuzzi,Lawrence A. Yannuzzi,Kathleen T. Rohrer,Kathleen T. Rohrer,Lori J. Tindel,Lori J. Tindel,Russell S. Sobel,Russell S. Sobel,Marcelle A. Costanza,Marcelle A. Costanza,William Shields,William Shields,Edith A. Zang,Edith A. Zang +13 more
TL;DR: In this survey, 2434 responding ophthalmologists reported on 221,781 fluorescein angiograms performed in the year 1984, with a frequency rate for a moderate reaction, for a severe reaction, and for death.
Journal ArticleDOI
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report
Wolf Szmuness,Wolf Szmuness,Cladd E. Stevens,Cladd E. Stevens,Edith A. Zang,Edith A. Zang,Edward J. Harley,Edward J. Harley,Aaron Kellner,Aaron Kellner +9 more
TL;DR: It is confirmed that a highly purified, formalin‐inactivated vaccine against hepatitis B prepared from HBsAg positive plasma, is safe immunogenic, and highly efficacious, and over 95% of vaccinated subjects developed antibody against the surface antigen.
Journal ArticleDOI
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.
Cladd E. Stevens,Harvey J. Alter,Patricia E. Taylor,Edith A. Zang,Edward J. Harley,Wolf Szmuness +5 more
TL;DR: This study did not demonstrate the efficacy of the vaccine in a population of patients receiving dialysis in whom both the rate of antibody response to hepatitis B vaccine and the viral attack rate were low, and other measures to control transmission of hepatitis B virus in dialysis units must be continued.